Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns

Pediatrics

Volumn 122, Issue 3, 2008, Pages

  Dubnov Raz, Gal ^a,b   Juurlink, David N ^c   Fogelman, Rami ^d   Merlob, Paul ^b   Ito, Shinya ^e   Koren, Gideon ^e   Finkelstein, Yaron ^e,f,g,h  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c Departments of Pediatric Cardiology   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e Pediatrics   (Canada)

^f Division of Clinical Pharmacology and Toxicology   (Canada)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adverse drug events; Antidepressant; Electrocardiography; Long QT syndrome; Pregnancy

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; ECG ABNORMALITY; FEMALE; GESTATIONAL AGE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; MATERNAL TREATMENT; MEASUREMENT; NEWBORN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SUDDEN DEATH; TERTIARY HEALTH CARE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DEPRESSION; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; FETUS HEART; FETUS HEART RATE; FOLLOW UP; HEART ARRHYTHMIA; INFANT MORTALITY; ISRAEL; MORTALITY; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY;

ARRHYTHMIAS, CARDIAC; DEPRESSION; ELECTROCARDIOGRAPHY; FEMALE; FETAL HEART; FOLLOW-UP STUDIES; GESTATIONAL AGE; HEART RATE, FETAL; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; ISRAEL; MALE; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 51649121787     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0658     Document Type: Article

References (47)

1. Schwartz PJ, Locati EH, Napolitano C, Priori SG. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia, PA: WB Saunders; 1995:788-811
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022
3. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ. 2005;172(6):765-767
4. Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health. 2003;12(4):373-380
5. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103(4):698-709
6. Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin- reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(2):2188-2189
7. Kallen B. Neonate characteristics after maternal use of antide- pressants in late pregnancy. Arch Pediatr Adolesc Med. 2004; 158(4):312-316
8. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482-487
9. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372-2383
10. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354(6):579-587
11. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906
12. Ferreira E, Carceller AM, Agoguee C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 2007;119(1): 52-59
13. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go- related gene (HERG) potassium channels. J Pharmacol Exp Ther. 2002;300(2):543-548
14. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 2002;512(1-3):59-66
15. Yap YG, Camm AJ. Drug-induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363-1372
16. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT- prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114(2):135-141
17. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45(5): 415-427
18. Varriale P. Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med. 2001;161(4):612
19. Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry. 2006; 163(2):325
20. Erfurth A, Loew M, Dobmeier P, Wendler G. ECG changes after paroxetine. 3 case reports. Nervenarzt. 1998;69(7): 629-631
21. RaviñaT, Suarez ML, Mendez-Castrillon J. Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int J Cardiol. 1998;65(3):311-313
22. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-285
23. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64(2):192-197
24. Dubnov G, Fogelman R, Merlob P. Prolonged QT interval in a newborn to a fluoxetine-treated mother. Arch Dis Child. 2005; 90(9):972-973
25. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997; 340(2-3):249 -258
26. Chia EL, Ho TF, Rauff M, Yip WC. Cardiac time intervals of normal fetuses using noninvasive fetal electrocardiography. Prenat Diagn. 2005;25(7):546 -552
27. Bazett H. An analysis of the time relationship of electrocardiograms. Heart. 1920;7:353-370
28. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med. 1998;338(24):1709-1714
29. Fridericia LS. Die Systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand. 1920;53:469-486
30. Garson A Jr. How to measure the QT interval: what is normal? Am J Cardiol. 1993;72(6):14B-16B
31. Garson A Jr. Electrocardiography. In: Garson A, Bricker JT, Fisher DJ, Neish SR, eds. The Science and Practice of Pediatric Cardiology. 2nd ed. Baltimore, MD: Williams and Wilkins; 1998
32. Flanagan MF, Yeager SB, Weindling SN. Cardiac disease. In: MacDonald MG, Mullett MD, Seshia MM, eds. Avery's Neonatology: Pathophysiology and Management of the Newborn. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005
33. Schwartz PJ, Garson A Jr, Paul T, et al. Guidelines for the interpretation of the neonatal electrocardiogram. Eur Heart J. 2002;23(17):1329-1344
34. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG. 2002;109(9): 1003-1008
35. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160(5):993-996
36. Loughhead AM, Fisher AD, Newport DJ, et al. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry. 2006;163(1):145-147
37. Johnston MV. Conditions that mimic seizures. In: Behrman RE, Kliegman RM, Jensen HB, eds. Nelson's Textbook of Pediatrics. 17th ed. Philadelphia, PA: WB Saunders; 2004; 2009-2012
38. Widerhorn J, Bhandari AK, Bughi S, Rahimtoola SH, Elkayam U. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am Heart J. 1991;122(4 pt 1): 1162-1166
39. Hussain T, Ewer AK. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr. 2007;96(5):768-769
40. Carboni MP, Garson A Jr. Ventricular arrhythmias. In: Garson A, Bricker JT, Fisher DJ, Neish SR, eds. The Science and Practice ofPediatric Cardiology. 2nd ed. Baltimore, MD: Williams and Wilkins; 1998
41. Hosono T, Kawamata K, Chiba Y, Kandori A, Tsukada K. Prenatal diagnosis of long QT syndrome using magnetocardiography: a case report and review of the literature. Prenat Diagn. 2002;22(3): 198 -200
42. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem. 1991; 202(2):583-588
43. Allegaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cyto- chrome P-450 2D6 activity. Br J Anaesth. 2005;95(2):231-239
44. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965-974
45. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS Pharm Sci. 2002;4(1):E4
46. Holladay JW, Dewey MJ, Yoo SD. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels. Drug Metab Dispos. 1998;26(1):20-24
47. Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants. Anesthesiology. 2003;98(3):639-642